Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. provides physician services for women, babies and children across hospital settings and office-based practices. Its recurring updates center on obstetrics, maternal-fetal medicine, neonatology, neonatal intensive care unit activity and other pediatric subspecialties, with revenue concentrated in neonatology and pediatric subspecialty care.
Company news also covers quarterly operating results, same-unit revenue trends, reimbursement and payor-mix factors, patient acuity, hospital contract administrative fees, practice acquisitions and dispositions, service expansions, clinical quality initiatives and neonatology education through NEO: The Conference for Neonatology.
Pediatrix Medical Group (NYSE: MD) is hosting the NEO: The Conference for Neonatology from February 22-24 in Las Vegas, Nevada. This premier event addresses critical issues in neonatal care, attracting over 385 healthcare professionals. The CDC recently reported a 4% increase in the U.S. premature birth rate, now at 10.49%, emphasizing the importance of specialized neonatal care. Pediatrix, serving nearly 1 million neonates annually, is dedicated to improving outcomes for high-risk infants. The conference will feature esteemed speakers and the presentation of the Legends in Neonatology Award.
Pediatrix Medical Group, Inc. (NYSE: MD) reported fourth-quarter earnings from continuing operations at $0.29 per share, down from $0.47 in the same quarter last year. Net revenue for Q4 2022 rose to $514 million, a year-over-year increase from $498.5 million. Adjusted EBITDA decreased to $66 million from $81 million in the prior year. The company faced challenges with revenue cycle management and reported a significant drop in funds received under the CARES Act, impacting revenue growth. Looking ahead, Pediatrix projects 2023 Adjusted EBITDA between $235 million to $245 million. The firm ended the year with a strong financial position despite recent challenges.
Pediatrix Medical Group (NYSE: MD) will hold an investor conference call on February 17, 2023, at 9:00 a.m. ET, to discuss operational results for the quarter ending December 31, 2022. A press release detailing these results will be issued on the same day before market opening. Pediatrix Medical Group is the leading provider of physician services in the U.S., specializing in obstetrics, maternal-fetal medicine, neonatology, and over 20 pediatric subspecialties. The company has grown significantly since its founding in 1979, now employing over 5,000 clinicians across 37 states.
Pediatrix Medical Group (NYSE: MD) has appointed James D. Swift, M.D., as the new Chief Executive Officer, succeeding Mark S. Ordan, who has transitioned to Executive Chair. This leadership change, effective at year-end, follows Ordan's tenure since July 2020, during which he oversaw significant strategic developments, including a focus on women's and children's care and a strengthening of the company's balance sheet. Dr. Swift has been with Pediatrix since 2009, previously serving as Chief Development Officer and COO.
Summary not available.
Pediatrix Medical Group, Inc. (NYSE:MD) will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 3:15 p.m. PT in Rancho Palos Verdes, California. The presentation will be available via live audio webcast on the company's website. Pediatrix is the leading provider of physician services, focusing on coordinated care for women, infants, and children across various specialties. The company operates with over 4,800 clinicians in 37 states and Puerto Rico.
Pediatrix Medical Group (NYSE: MD) reported Q3 2022 earnings of $0.35 per share, with net revenue of $490 million, down from $492.9 million year-over-year. Adjusted EBITDA was $58 million, reflecting operational challenges in billing and collections, and a decline in reimbursement from commercial payors. Despite these issues, Pediatrix's Adjusted EPS from continuing operations was $0.40. The company anticipates 2022 Adjusted EBITDA will range from $240 million to $245 million, indicating strategic efforts are underway to enhance revenue cycle management.
Pediatrix Medical Group, Inc. (NYSE: MD) will hold an investor conference call on November 3, 2022, at 9:00 a.m. ET to discuss its quarterly operational results for the period ending September 30, 2022. A detailed press release will precede the call, providing insights into the company's financial performance. The call will be accessible via webcast on the company's investor relations page. Pediatrix is a leading provider of physician services focused on pediatrics and obstetrics, serving across 37 states and Puerto Rico.
Pediatrix Medical Group, Inc. (NYSE: MD) commented on the final rule from August 19, 2022, regarding the No Surprises Act. The rule stipulates that the qualifying payment amount (QPA) is one of several factors considered in the independent dispute resolution (IDR) process for out-of-network payment rates. Key factors include provider training, market share, patient acuity, facility status, and good faith negotiations. Pediatrix emphasizes the importance of safeguarding against potential payor manipulation of the QPA and is committed to ensuring compliance with the new rules for the continuity of care.
Pediatrix Medical Group, Inc. (NYSE: MD) reported earnings from continuing operations of $0.36 per share for Q2 2022, with Adjusted EPS of $0.47. The company achieved net revenue of $486 million, a 2.7% increase from the prior year, primarily due to acquisitions. However, same-unit revenue decreased by 1.3%. Operating expenses rose to $330.8 million, reflecting acquisitions. Adjusted EBITDA for Q2 was $66 million. Cash from continuing operations was $81.6 million. The company anticipates 2022 Adjusted EBITDA between $260-$270 million.